Ad
AQXP - Aquinox Pharmaceuticals Stock Trading
About | Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)
Not available
Quote | Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)
| Last: | $ |
|---|---|
| Change Percent: | 6.05% |
| Open: | $3.50 |
| Close: | $3.68 |
| High: | $3.84 |
| Low: | $3.46 |
| Volume: | 513,928 |
| Last Trade Date Time: | 08/09/2019 04:46:39 pm |
News | Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)
-
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
-
Nasdaq Ticker Symbol “NLTX” to be effective Monday, August 12, 2019 SEATTLE, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Message Board Posts | Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)
| Subject | By | Source | When |
|---|---|---|---|
| agreed! | wesley_ | investorshub | 08/08/2019 3:56:51 PM |
| Very nice thin mover, not done imo | Klinsmann | investorshub | 08/08/2019 3:45:04 PM |
| $3.56 on nice volume, loaded some | wesley_ | investorshub | 08/08/2019 3:00:07 PM |
| Aweiner | investorshub | 05/02/2019 2:50:42 PM | |
| 20% up - not too shabby and on | Klinsmann | investorshub | 02/14/2019 5:44:13 PM |
News, Short Squeeze, Breakout and More Instantly...
Aquinox Pharmaceuticals Inc. Company Name:
AQXP Stock Symbol:
NASDAQ Market:
Aquinox Pharmaceuticals Inc. Website:
Ad
-
Nasdaq Ticker Symbol “NLTX” to be effective Monday, August 12, 2019 SEATTLE, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
-
SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, and Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP),...
-
• Combined company capitalized with approximately $65M to develop novel immunotherapies • Sophisticated computational platform enables new class of de novo protein therapeutics • Lead program, NL-201, is a potent IL-2/IL-15 agonist with favorable t...